

# Toronto General Hospital ANTIBIOGRAM

## All Inpatients and Outpatients

### January 1, 2014 - December 31, 2014

#### Blood Isolates – % Susceptible

			<div style="display: flex; align-items: center; gap: 10px;"> <div style="text-align: center;"> <p>≥80% Susceptible <span style="color: green;">■</span></p> <p>70-79% Susceptible <span style="color: yellow;">■</span></p> <p>≤69% Susceptible <span style="color: red;">■</span></p> </div> <div style="text-align: center;">%</div> </div>					Fluconazole	Voriconazole	Caspofungin	Micafungin	Anidulafungin
			ALL CANDIDA	35	100							
<i>Candida albicans</i>	17	49	100	100	100	100	100	100				
<i>Candida parapsilosis</i>	7	20	100	100	100	100	100	100				
<i>Candida glabrata</i> *	6	17	83		83	83	83	83				
<i>Candida dubliniensis</i>	2	6	100	100	100	100	100	100				
<i>Candida guilliermondii</i>	1	3	100	100	100	100	100	100				
<i>Candida krusei</i> **	1	3		100	100	100	100	100				
<i>Candida lusitanae</i> ^	1	3										

#### Year-Specific Notes:

- Interpretive standards for fluconazole, voriconazole, caspofungin, micafungin and anidulafungin susceptibility for all *Candida spp.* were changed in 2013 resulting in an apparent drop in susceptibility to some of these antifungal agents compared to past years.

#### Organism-Specific Notes:

\* *Candida glabrata* - There are no interpretative breakpoints for voriconazole. There are no susceptibility breakpoints for fluconazole, the percentage provided refers to the percentage of *Candida glabrata* that are susceptible dose-dependent.

\*\* *Candida krusei* - There are no interpretative breakpoints for fluconazole.

^ *Candida lusitanae* - There are no interpretative breakpoints for any antifungal.

---

Prepared by University Health Network/Mount Sinai Hospital Department of Microbiology

May 26, 2016